Eli Lilly & Co. Upgraded to Hold at Edward Jones (LLY)
Eli Lilly & Co. (NYSE:LLY) was upgraded by analysts at Edward Jones from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Thursday, Analyst Ratings Net reports.
Eli Lilly & Co. (NYSE:LLY) traded up 1.71% during mid-day trading on Thursday, hitting $48.78. The stock had a trading volume of 2,232,281 shares. Eli Lilly & Co. has a one year low of $44.88 and a one year high of $58.40. The stock’s 50-day moving average is $51.71 and its 200-day moving average is $53.23. The company has a market cap of $52.692 billion and a P/E ratio of 10.77.
Eli Lilly & Co. (NYSE:LLY) last issued its quarterly earnings data on Wednesday, July 24th. The company reported $1.16 earnings per share for the quarter, beating the analysts’ consensus estimate of $1.01 by $0.15. The company had revenue of $5.93 billion for the quarter, compared to the consensus estimate of $5.82 billion. During the same quarter last year, the company posted $0.83 earnings per share. Eli Lilly & Co.’s revenue was up 5.9% compared to the same quarter last year. Analysts expect that Eli Lilly & Co. will post $4.14 EPS for the current fiscal year.
A number of other firms have also recently commented on LLY. Analysts at Credit Suisse initiated coverage on shares of Eli Lilly & Co. in a research note to investors on Tuesday. They set a “neutral” rating on the stock. Separately, analysts at Argus cut their price target on shares of Eli Lilly & Co. from $63.00 to $56.00 in a research note to investors on Monday. They now have a “buy” rating on the stock. Finally, analysts at UBS AG cut their price target on shares of Eli Lilly & Co. from $52.00 to $50.00 in a research note to investors on Friday, October 4th. They now have a “neutral” rating on the stock. One research analyst has rated the stock with a sell rating, ten have given a hold rating and nine have issued a buy rating to the stock. The company has an average rating of “Hold” and an average price target of $56.13.
Eli Lilly and Company discovers, develops, manufactures, and sells products, in one business segment, pharmaceutical products.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.